Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;77(7):979-987.
doi: 10.1007/s00228-020-03060-2. Epub 2021 Jan 16.

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs

Perrine Courlet  1 , Monia Guidi  1   2   3 , Susana Alves Saldanha  1 , Matthias Cavassini  4 , Marcel Stoeckle  5 , Thierry Buclin  1 , Catia Marzolini  5 , Laurent A Decosterd  1 , Chantal Csajka  6   7   8
Affiliations

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs

Perrine Courlet et al. Eur J Clin Pharmacol. 2021 Jul.

Abstract

Purpose: Drug-drug interactions (DDIs) with antiretroviral drugs (ARVs) represent an important issue in elderly people living with HIV (PLWH). Amlodipine is a commonly prescribed antihypertensive drug metabolized by CYP3A4, thus predisposed to a risk of DDIs. Guidance on the management of DDIs is mostly based on theoretical considerations derived from coadministration with other CYP3A4 inhibitors. This study aimed at characterizing the magnitude of DDIs between amlodipine and ARV drugs in order to establish dosing recommendations.

Methods: A population pharmacokinetic analysis was developed using non-linear mixed effect modelling (NONMEM) and included 163 amlodipine concentrations from 55 PLWH. Various structural and error models were compared to characterize optimally the concentration-time profile of amlodipine. Demographic and clinical characteristics as well as comedications were tested as potential influential covariates. Model-based simulations were performed to compare amlodipine exposure (i.e. area under the curve, AUC) between coadministered ARV drugs.

Results: Amlodipine concentration-time profile was best described using a one-compartment model with first-order absorption and a lag-time. Amlodipine apparent clearance was influenced by both CYP3A4 inhibitors and efavirenz (CYP3A4 inducer). Model-based simulations revealed that amlodipine AUC increased by 96% when coadministered with CYP3A4 inhibitors, while efavirenz decreased drug exposure by 59%.

Conclusion: Coadministered ARV drugs significantly impact amlodipine disposition in PLWH. Clinicians should adjust amlodipine dosage accordingly, by halving the dosage in PLWH receiving ARV with inhibitory properties (mainly ritonavir-boosted darunavir), whereas they should double amlodipine doses when coadministering it with efavirenz, under appropriate monitoring of clinical response and tolerance.

Keywords: Amlodipine; Drug-drug interactions; HIV; NONMEM; Pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

MC has received through his institution research grant from ViiV, Gilead, and offered expert testimony for Abbvie, MSD, Gilead, and Sandoz. MS received payments for advisory boards from Gilead, ViiV, MSD, Sandoz and Mepha, as well as travel grants for conferences from Gilead and MSD, yet unrelated to the present study. CM received a research grant from Gilead and speaker honoraria for her institution from MSD. All other authors: none to declare.

Figures

Fig. 1
Fig. 1
pcVPC of amlodipine final model with amlodipine prediction-corrected concentrations (open circles), median of the observed concentrations (solid line) with 90% prediction interval (dashed lines). Grey fields represent the model-based 90% confidence interval of the simulated median and PI90%
Fig. 2
Fig. 2
Simulated amlodipine plasma concentrations for dosage regimens of 2.5 mg qd with CYP3A4 inhibitors (i.e. ritonavir-boosted darunavir, cobicistat-boosted darunavir, ritonavir-boosted atazanavir, cobicistat-boosted elvitegravir) (left) or 10 mg qd with efavirenz (right), compared with standard dosage of 5 mg qd. Continuous line represent the population median prediction for standard (grey) and alternative regimens (orange), while shaded areas and dashed lines represent the 90% prediction interval based on 1000 simulated PLWH
See this image and copyright information in PMC

References

    1. Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG, Adult ACTGAPT. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther. 2005;78(2):143–153. doi: 10.1016/j.clpt.2005.04.005. - DOI - PubMed
    1. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011;55(10):4569–4574. doi: 10.1128/AAC.00653-11. - DOI - PMC - PubMed
    1. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22(1):22–31. doi: 10.2165/00003088-199222010-00003. - DOI - PubMed
    1. Food and Drug Administration. Norvasc, Summary of Product Characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf. Accessed 7 June 2019
    1. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20–29. doi: 10.1016/j.jhep.2015.01.026. - DOI - PubMed

LinkOut - more resources